GDSC2
A large-scale public database jointly maintained by the Wellcome Sanger Institute and Massachusetts General Hospital. It records in vitro drug sensitivity metrics (IC50/AUC) for human cancer cell lines tested against candidate anti-cancer compounds, and serves as a standard benchmark database in pharmacogenomics research.
Timeline (last 90 days)
The study performs modeling and validation based on 242,036 drug sensitivity measurements from the GDSC2 database.
GDSC2 is a large-scale public database jointly maintained by the Sanger Institute in the UK and Massachusetts General Hospital, recording in vitro drug sensitivity metrics such as IC50 or AUC for cancer cell lines against candidate anticancer compounds.
All Facts (2)
The study performs modeling and validation based on 242,036 drug sensitivity measurements from the GDSC2 database.
50%UnverifiedGDSC2 is a large-scale public database jointly maintained by the Sanger Institute in the UK and Massachusetts General Hospital, recording in vitro drug sensitivity metrics such as IC50 or AUC for cancer cell lines against candidate anticancer compounds.
50%